At Sanaria we are working on a completely different approach to malaria vaccine development. The goal is to develop a practically manufactured and administered, safe, non-toxic, effective, non-replicating, metabolically active, whole parasite P. falciparum sporozoite vaccine. This approach is based on the fact that when the immunogens, radiation attenuated P. falciparum sporozoites, are administered via the bites of infected mosquitoes, they elicit immune responses that completely protect greater than 90% of recipients against experimental P. falciparum challenge for at least 10 months. Current status of these and other approaches to develop vaccines to reduce the 2,700 to 8,100 daily deaths in infants and children in Africa will be discussed.

Anyone outside NIST wishing to attend must be sponsored by a NIST employee and receive a visitor badge. For more information, call Kum J. Ham at 301-975-4203.

Colloquia are videotaped and available in the NIST Research Library.